Pharmaceutical company Pfizer and its partner BioNTech announced this Thursday that they will soon order Authorize a booster dose of your COVID-19 vaccine for children ages 5 through 11after a study has shown that it significantly increases antibodies against the omicron variant.

The clinical trial analyzed data from 140 children who received this third dose approximately six months after the second and documented that antibodies against omicron were 36 times higher in these cases.

According to the companies, the vaccine was well tolerated and raised no new safety issues.. In total, more than 10,000 children under the age of 12 have so far participated in studies on this vaccine.

In a statement, Pfizer and BioNTech announced that they plan to request “in the next few days” the emergency authorization of this booster dose for children ages 5 to 11 in the United States.

In addition, they said that they will share data as soon as possible with the European Medicines Agency (EMA) and with regulators from other countries.

Both the US and European regulators have already approved booster doses of the Pfizer vaccine for both adults and the 12- to 17-year-old age group.

Categorized in: